On this page we show you what each team did and where similarities and where differences areff. If you have specific questions about a method or the general idea of the project just write us an email and we will get in contact with you or check out the teams individual wiki pages for more details.
-
Darmstadt
Mail: igem@bio.tu-darmstadt.de -
Kaiserslautern
Mail: igem@bio.uni-kl.de -
Stuttgart
Mail: Igem@ibvt.uni-stuttgart.de
Catalyzed Reaction
Laccases are multicopper oxidoreductases which are able to oxidize a wide variety of substrates either directly or indirectly. In the direct oxidation, the substrate interacts with the laccase‘s copper cluster. The indirect oxidation involves a mediator which is oxidized by the laccase. The mediator then oxidizes the substrate[1].
In the course of the reaction, one electron is transferred from the substrate to the copper cluster, turning the substrate into a radical[1]. After four substrate molecules are oxidized in this manner, the enzyme‘s fully reduced copper cluster then binds molecular oxygen. Two consecutive two-electron reductions then form two water molecules, putting the enzyme back into its oxidized form[1],[2] (Fig. 1).
In the course of the reaction, one electron is transferred from the substrate to the copper cluster, turning the substrate into a radical[1]. After four substrate molecules are oxidized in this manner, the enzyme‘s fully reduced copper cluster then binds molecular oxygen. Two consecutive two-electron reductions then form two water molecules, putting the enzyme back into its oxidized form[1],[2] (Fig. 1).
In this section we summarized the workflows of our projects. By doing so we try to give future teams an overview over the complexity of such a project. Also, this makes it easier for the reader to compare our projects.
iGEM TU Darmstadt
In our project B-Tox, we aim to positively impact the fight against environmental pollution. Diclofenac and antibiotics are micropollutants of special interest, as their harmful accumulation in our environment is yet unbroken. We aim to use laccases and antibiotic-specific esterases to render both micropollutants less harmful and therefore display them on the biofilm matrix protein TasA in an engineered Bacillus subtilis biofilm for the use in wastewater treatment plants.
a) We tested the biofilm durability in our self-designed flow chamber and aim to measure the sorption capacity of compounds of interest (e.g. diclofenac) to ensure that our host B.&npsb;subtilis is producing a biofilm which is suitable for our application. Afterwards, we aim to produce a TasA-sfGFP fusion protein in our strain and test whether fusion proteins of TasA and a second domain inhibit biofilm formation in B. subtilis.
b) Besides enabling the generation of an engineered biofilm, we also have to investigate whether our enzymes are active. Consequently, we recombinantly express and purify our enzymes in E. coli and characterize their properties in vitro. Enzymatic activity will be tested in defined periods with coupled analysis via HPLC. Furthermore, we want to confirm that the degradation products of our targeted micropollutants are less toxic and therefore aim to conduct a toxicity assays .
c) After successfully testing our biofilm and our enzymes as described in section a) and b) plasmids encoding both components will be cloned in E. coli and subsequently transformed into B. subtilis and integrated into the genome. At this stage of our project we aim to use our designed flow chamber once more for testing the durability and stability of our engineered biofilm harbouring immobilized enzymes. Eventually, we aim to measure the degradation characteristics of our modified biofilm by incubating degradation substrates with the biofilm and analyze samples of time points via HPLC.
d) We want to apply our modified biofilm in a wastewater treatment plant and therefore in direct contact to our freshwater supply. For biosafety reasons, we developed a novel quorum sensing-based kill switch. This kill switch will act as an additional safety measure complementing physical containment.
We are aware that this concept has yet to be practically tested and that we cannot yet state that it will be successful. However, we believe that the concept of a modular B. subtilis biofilm that can be introduced into wastewater treatment plants for degradation of problematic organic compounds has the potential to expand our methods in eliminating environmental pollution and purifying drinking water.
a) We tested the biofilm durability in our self-designed flow chamber and aim to measure the sorption capacity of compounds of interest (e.g. diclofenac) to ensure that our host B.&npsb;subtilis is producing a biofilm which is suitable for our application. Afterwards, we aim to produce a TasA-sfGFP fusion protein in our strain and test whether fusion proteins of TasA and a second domain inhibit biofilm formation in B. subtilis.
b) Besides enabling the generation of an engineered biofilm, we also have to investigate whether our enzymes are active. Consequently, we recombinantly express and purify our enzymes in E. coli and characterize their properties in vitro. Enzymatic activity will be tested in defined periods with coupled analysis via HPLC. Furthermore, we want to confirm that the degradation products of our targeted micropollutants are less toxic and therefore aim to conduct a toxicity assays .
c) After successfully testing our biofilm and our enzymes as described in section a) and b) plasmids encoding both components will be cloned in E. coli and subsequently transformed into B. subtilis and integrated into the genome. At this stage of our project we aim to use our designed flow chamber once more for testing the durability and stability of our engineered biofilm harbouring immobilized enzymes. Eventually, we aim to measure the degradation characteristics of our modified biofilm by incubating degradation substrates with the biofilm and analyze samples of time points via HPLC.
d) We want to apply our modified biofilm in a wastewater treatment plant and therefore in direct contact to our freshwater supply. For biosafety reasons, we developed a novel quorum sensing-based kill switch. This kill switch will act as an additional safety measure complementing physical containment.
We are aware that this concept has yet to be practically tested and that we cannot yet state that it will be successful. However, we believe that the concept of a modular B. subtilis biofilm that can be introduced into wastewater treatment plants for degradation of problematic organic compounds has the potential to expand our methods in eliminating environmental pollution and purifying drinking water.
iGEM TU Kaiserslautern
Our project involves the transformation of the green algae Chlamydomonas reinhardtii, enabling the chemical modification of diclofenac, resulting in its functional degradation. We will integrate genes for the enzyme laccase into the genome of our green algae, as well as perform a control by cloning the genes into the bacterium Escherichia coli. This will facilitate the production of these enzymes and secretion into medium (the wastewater from wastewater treatment plants), where they can then break down diclofenac. We split into 3 teams to best implement our experimental process: one team focused on producing proteins with our model organism called Chlamy Team, one focused on doing the same with our control organism called E. coli Team, and our Assay Team who performed the confirmation activity assays with both previous teams’ produced laccases.
Chlamy Team:
Vectors with the genes for the laccases BaLac and MarLac were produced via modular cloning (MoClo). All level 2 multigene constructs included a spectinomycin resistance cassette for later selection. After transformation in Chlamydomonas reinhardtii by electroporation, the algae were plated on TAP agar plates containing spectinomycin. Random colonies were picked and inoculated in fluid culture for screening. The cells were lysed and centrifuged to separate the debris from the supernatant, containing the soluble laccases. SDS-Page and a subsequent Western Blot were performed to find positive transformants. All laccase-producing cultures were inoculated again in fluid culture and prepared for ABTS Assay and HPLC Assay.
E.coli Team:
The vector was obtained through in vitro synthesis and purchased from General Biosystems. First, two vectors which include the gene for one of the laccases (BaLac or MarLac) , a tac promoter and an ampicillin resistance were transformed into E. coli. The transformed E.coli was grown on LB-plates with ampicillin to select for the colonies that took up the vector. One colony was chosen and produced in a fluid culture with which proteins were expressed. Production was induced with IPTG. After expression, proteins were purified with GST-Sepharose columns. The concentrated protein was then ready to be tested with ABTS or HPLC. As a visible proof that laccases were produced, SDS-PAGE and Western Blot screening was performed.
Assay Team:
Because ABTS interacts with laccase in a similar way to the laccase-diclofenac interaction, a series of ABTS assays were performed to determine reaction strength. To begin, the optimal wavelength for ABTS was confirmed via spectrometer. An assay was then performed to visualize the positive control laccase from Trametes versicolor at the two optimal pH’s documented for BaLac (pH 4) and MarLac (pH 7), as well as its own optimal pH 5. In a 96 well plate, varying concentrations of the positive control laccase at different pH levels were added to the substrate. Once produced, we ran the same assay with the manufactured BaLac and MarLac laccases (both intracellular and secreted, depending what was produced) at their optimal pH and compared it against the positive control to confirm activity.
HPLC was run first with Diclofenac to verify standard retention time, then a positive control reaction with T. versicolor to determine the products to compare them against the produced enzymes. Finally, the manufactured laccase products were analyzed.
To ensure an efficient enzyme production, Chlamydomonas will be raised as a permanent culture in a bioreactor. To separate the green algae from the wastewater, we want to create a filter between the bioreactor and the wastewater basin that only allows the enzymes to pass through. The degradation products show no toxicity and therefore do not harm the environment.
Chlamy Team:
Vectors with the genes for the laccases BaLac and MarLac were produced via modular cloning (MoClo). All level 2 multigene constructs included a spectinomycin resistance cassette for later selection. After transformation in Chlamydomonas reinhardtii by electroporation, the algae were plated on TAP agar plates containing spectinomycin. Random colonies were picked and inoculated in fluid culture for screening. The cells were lysed and centrifuged to separate the debris from the supernatant, containing the soluble laccases. SDS-Page and a subsequent Western Blot were performed to find positive transformants. All laccase-producing cultures were inoculated again in fluid culture and prepared for ABTS Assay and HPLC Assay.
E.coli Team:
The vector was obtained through in vitro synthesis and purchased from General Biosystems. First, two vectors which include the gene for one of the laccases (BaLac or MarLac) , a tac promoter and an ampicillin resistance were transformed into E. coli. The transformed E.coli was grown on LB-plates with ampicillin to select for the colonies that took up the vector. One colony was chosen and produced in a fluid culture with which proteins were expressed. Production was induced with IPTG. After expression, proteins were purified with GST-Sepharose columns. The concentrated protein was then ready to be tested with ABTS or HPLC. As a visible proof that laccases were produced, SDS-PAGE and Western Blot screening was performed.
Assay Team:
Because ABTS interacts with laccase in a similar way to the laccase-diclofenac interaction, a series of ABTS assays were performed to determine reaction strength. To begin, the optimal wavelength for ABTS was confirmed via spectrometer. An assay was then performed to visualize the positive control laccase from Trametes versicolor at the two optimal pH’s documented for BaLac (pH 4) and MarLac (pH 7), as well as its own optimal pH 5. In a 96 well plate, varying concentrations of the positive control laccase at different pH levels were added to the substrate. Once produced, we ran the same assay with the manufactured BaLac and MarLac laccases (both intracellular and secreted, depending what was produced) at their optimal pH and compared it against the positive control to confirm activity.
HPLC was run first with Diclofenac to verify standard retention time, then a positive control reaction with T. versicolor to determine the products to compare them against the produced enzymes. Finally, the manufactured laccase products were analyzed.
To ensure an efficient enzyme production, Chlamydomonas will be raised as a permanent culture in a bioreactor. To separate the green algae from the wastewater, we want to create a filter between the bioreactor and the wastewater basin that only allows the enzymes to pass through. The degradation products show no toxicity and therefore do not harm the environment.
iGEM Stuttgart
Our project LAC-MAN focusses on water purification from pharmaceuticals such as diclofenac (a pain reliever) and carbamazepine (anticonvulsant medication) using laccases. Laccase is a class of enzyme which is able to neutralize a large number of pollutants. In our project, they are immobilized to a mesoporous silica foam, giving them more long-term sustainability and making them more pH- and thermostable. Silicon-based materials are well suited to this task because they are environmentally friendly, biocompatible and, above all, resistant to organic solvents and microbial attacks. Since the enzymes are bound to a matrix, no genetically modified organisms are released into the environment. Furthermore, the degraded products no longer have either negative effects or toxic properties. In the following figure and corresponding description, a summary is provided about the applied methods used in our project.
Issue | Darmstadt | Kaiserslautern | Stuttgart |
---|---|---|---|
Used Enzymes | Laccase: CotA of Bacillus subtilis and CueO of Escherichia coli
Esterase: EreB of Escherichia coli |
Synthesized: Botrytis aclada laccase (BaLac) and unknown mutated marine laccase (MarLac)
Control: Trametes versicolor laccase |
Laccases of Trametes versicolor and Streptomyces cyaneus |
Model Organism | Bacillus subtilis and Escherichia coli |
Green algae Chlamydomonas reinhardtii and Escherichia coli as comparison |
Pichia pastoris and Escherichia coli |
Special Technique | Immobilization of the enzymes in the matrix of the Bacillus subtilis biofilm |
Laccase secretion and filtration before access to wastewater |
Immobilization of the enzymes in a silica foam |
Tested Substrates | Laccases:
ABTS Diclofenac EreB: Erythromycin Azithromycin |
ABTS
Diclofenac |
ABTS
Diclofenac Carbamazepine |
Genetic Engineering | Construct Assembly: Gibson Assembly
Genomic Integration: Homologous Recombination |
Chlamydomonas reinhardtii: MoClo
Escherichia coli: ordered/ synthesized plasmid |
Restriction digest
|
Fun Facts | Overgrad team with 81% undergrad students |
Only team from Rhineland-Palatinate |
13 German potatoes and one Egyptian |
ABTS reaction
As you can see in the table we use ABTS as one of our preferred substances for measuring enzyme activity. This is the case because ABTS has a high throughput in the catalyzed reaction and the oxidation product triggers a colour change that can be photometrically measured.
To visualize where our projects will be implemented in a wastewater treatment plant we designed the following overview. If you cannot remember what happens in the respective installations just have a look again in the table on our overview page. You will not find a fourth purification stage there, as these are not implemented yet and are therefore hard to include into a generalized image. Examples for technologies that are already implemented are ozonolysis and actived carbon.
In this section you find our ideas for further collaboration. Sadly, these ideas could not be realized this year due to COVID-19.
-
Immobilization of all three teams laccases in Stuttgart´s silica foam/ Darmstadt´s biofilm.
We could have exchanged our laccases and tried to immobilize the all different laccases according to our protocols to compare each laccase effectiveness. Potentially higher immobilization efficiencies and higher temperature/pH resistances could have been achieved. -
Analyzing samples of each other to confirm results with different analytical methods.
Different biodegradation samples of pharmaceutical residues could have been exchanged to be analyzed by the other teams with their specific analytical methods. Thereby, the obtained experimental results could have been confirmed by the other teams. -
Laccase Exchange.
We could have tested the different chosen laccases and whether they are able to degrade the other teams substrates as well to a certain extent. -
Development of further modules for Darmstadt`s flow chamber.
This includes a module for silica foam of Stuttgart and for Chlamydomonas Rheinhardtii of Kaiserslautern. -
Stability test via Atomic Force Microscopy (AFM) by Kaiserslautern.
Kaiserslautern coud have tested the stability of Darmstadt`s biofilm in the AFM. -
Construction of a filter element.
The teams Stuttgart and Darmstadt could have cooperated in designing a filter element that could be practically deployed in a sewage plant. In the filter element the biofilm or the silica foam with immobilized enzyme could be included.
References
[1] Agrawal, K.; Chaturvedi, V.; Verma, P. Fungal Laccase Discovered but yet Undiscovered. Bioresour. Bioprocess. 2018, 5 (1), 4. https://doi.org/10.1186/s40643-018-0190-z. [2] Zerva, A.; Simić, S.; Topakas, E.; Nikodinovic-Runic, J. Applications of Microbial Laccases: Patent Review of the Past Decade (2009–2019). Catalysts 2019, 9 (12), 1023. https://doi.org/10.3390/catal9121023. [3] Hahn, V. Enhanced Laccase-Mediated Transformation of Diclofenac and Flufenamic Acid in the Presence of Bisphenol A and Testing of an Enzymatic Membrane Reactor. 2018, 11. https://doi.org/10.1007/s00253-013-5055-y [4] Marco-Urrea, E.; Pérez-Trujillo, M.; Cruz-Morató, C.; Caminal, G.; Vicent, T. Degradation of the Drug Sodium Diclofenac by Trametes Versicolor Pellets and Identification of Some Intermediates by NMR. Journal of Hazardous Materials 2010, 176 (1–3), 836–842. https://doi.org/10.1016/j.jhazmat.2009.11.112. [5] Re, R.; Pellegrini, N.; Proteggente, A.; Pannala, A.; Yang, M.; Rice-Evans, C. Antioxidant Activity Applying an Improved ABTS Radical Cation Decolorization Assay. Free Radical Biology and Medicine 1999. https://doi.org/10.1016/S0891-5849(98)00315-3.